Nature Medicine, Published online: 26 November 2025; doi:10.1038/d41591-025-00068-y
A phase 1 trial suggests safety, tolerability and immunogenicity of a candidate subunit vaccine against the deadly Nipah virus, for which countermeasures are urgently needed.
